4D Molecular (FDMT) Therapeutics announced senior leadership additions and changes that align with the Company’s focus on late-stage clinical trial and BLA execution and commercial readiness. Julie Clark, M.D., was promoted to Chief Medical Officer, CMO. Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality. Robert Kim, M.D., has stepped down from his role as Chief Medical Officer to pursue other opportunities, effective August 30, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- Buy Rating Affirmed for 4D-150: Promising Phase 2a SPECTRA Trial Results and Market Potential
- 4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape
- 4D Molecular Therapeutics Advances Clinical Programs in Q2 2025
- 4D Molecular price target lowered to $16 from $17 at Leerink
- Morning Movers: MeridianLink jumps after pact to be acquired by Centerbridge